EVGN - CIK 0001574565
The table below shows Evogene Ltd.'s income statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | -$241.00K | $3.20M | $1.49M | $766.00K | $163.00K | $466.00K |
| R&D | $7.99M | $12.51M | $16.20M | $20.79M | $21.13M | $17.29M |
| SG&A |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $4.29M |
| $6.99M |
| $5.38M |
| $6.48M |
| $7.25M |
| $5.32M |
| Operating income | - | - | - | - | - | - |
| Income tax | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - |
| EPS (diluted) | - | - | - | - | - | - |